Xiao-Ying Xu

Xiao-Ying Xu

Auto-generated profile, based on publicly available information

Xiao-Ying Xu

Novartis Institutes for BioMedical Research, Translational Medicine, East Hanover, NJ, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2024 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
JDJohn D. Davis
John D. Davis
MPMarçal Bravo Padros
Marçal Bravo Padros
DCDaniela J. Conrado
Daniela J. Conrado
SGSamit Ganguly
Samit Ganguly
XGXiaowen Guan
Xiaowen Guan
MZMin Zhu
Min Zhu
Subcutaneous (s.c.) administration of monoclonal antibodies (mAbs) can reduce treatment burden for patients and healthcare systems compared with intravenous (i.v.) infusion through shorter administration times, made possible by convenient, patient‐centric devices. A deeper understanding of clinical pharmacology principles related to efficacy and safety of s.c.‐administered mAbs over the past decade has streamlined s.c. product development. This review presents learnings from key constituents of the s.c. mAb development pathway, including pharmacology, administration variables, immunogenicity, and delivery devices. Restricted mAb transportation through the hypodermis explains their incomplete absorption at a relatively slow rate (pharmacokinetic (PK)) and may impact mAb‐cellular interactions and/or onset and magnitude of physiological responses (pharmacodynamic). Injection volumes, formulation, rate and site of injection, and needle attributes may affect PKs and the occurrence/severity of adverse events like injection‐site reactions or pain, with important consequences for treatment adherence. A review of immunogenicity data for numerous compounds reveals that incidence of anti‐drug antibodies (ADAs) is generally comparable across i.v. and s.c. routes, and complementary factors including response magnitude (ADA titer), persistence over time, and neutralizing antibody presence are needed to assess clinical impact. Finally, four case studies showcase how s.c. biologics have been clinically developed: (i) by implementation of i.v./s.c. bridging strategies to streamline PD‐1/PD‐L1 inhibitor development, (ii) through co‐development with i.v. presentations for anti‐severe acute respiratory syndrome‐coronavirus 2 antibodies to support rapid deployment of both formulations, (iii) as the lead route for bispecific T cell engagers (BTCEs) to mitigate BTCE‐mediated cytokine release syndrome, and (iv) for pediatric patients in the case of dupilumab.

1 September 2010 in Tetrahedron Letters
Verified
Journal Article
Closed access
JFJi-Ya Fu
Ji-Ya Fu
QHQingchun Huang
Qingchun Huang
QWQiao-Wei Wang
Qiao-Wei Wang
LWLi-Xin Wang
Li-Xin Wang
XXXiao-Ying Xu
Xiao-Ying Xu

10 July 2024 in American Journal of Transplantation
Verified
Journal Article
Open access
JAJohanna R. Abend
Johanna R. Abend
ASAtul Sathe
Atul Sathe
MWMatthias B. Wrobel
Matthias B. Wrobel
MKMark Knapp
Mark Knapp
LXLucy Xu
Lucy Xu
SKSteven J. Kovacs
Steven J. Kovacs
Reactivation of BK polyomavirus (BKPyV) can cause significant kidney and bladder disease in immunocompromised patients. There are currently no effective, BKPyV-specific therapies. MAU868 is a novel, human IgG1 monoclonal antibody that binds the major capsid protein VP1 of BKPyV with picomolar affinity, neutralizes infection by the four major BKPyV genotypes (EC50 ranging from 0.009 to 0.093 μg/ml; EC90 ranging from 0.102 to 4.160 μg/ml), and has comparable activity against variants with highly prevalent VP1 polymorphisms. No resistance-associated variants were identified in long-term selection studies, indicating a high in vitro barrier-to-resistance. The high-resolution crystal structure of MAU868 in complex with VP1 pentamer identified three key contact residues in VP1 (Y169, R170, K172). A first-in-human study was conducted to assess the safety, tolerability, and pharmacokinetics of MAU868 following intravenous and subcutaneous administration to healthy adults in a randomized, placebo-controlled, double-blinded, single ascending dose design. MAU868 was safe and well-tolerated. All adverse events were Grade 1 and resolved. The pharmacokinetics of MAU868 was typical of a human IgG, with dose-proportional systemic exposure and an elimination half-life ranging between 23 and 30 days. These results demonstrate the potential of MAU868 as a first-in-class therapeutic agent for the treatment or prevention of BKPyV disease.

2 April 2019 in Synlett
Verified
Journal Article
Closed access
PDF file
HCHui Chen
Hui Chen
HLHui Liu
Hui Liu
SZSi-Han Zhao
Si-Han Zhao
SCShao-Bing Cheng
Shao-Bing Cheng
XXXiao-Ying Xu
Xiao-Ying Xu
XZXiao-Mei Zhang
Xiao-Mei Zhang
A highly enantioselective arylation of 3-carboxamide oxoindoles with quinone monoimines is described. Various 3-aryl-3-carboxamide oxindoles with an all-carbon quaternary center were obtained in moderate to good yields (up to 99%) with moderate to good enantioselectivities (up to 98%) in the presence of a bifunctional thiourea-tertiary amine catalyst. The absolute configuration of one product was determined by an X-ray crystal structural analysis and the absolute configurations of the other products can be assigned by analogy. Moreover, several chiral spirooxindole-benzofuranones were synthesized from the 3-aryl-3-carboxamide oxindoles in moderate yields with moderate to good enantioselectivities.